Used primarily as a long-acting antipsychotic agent in the management of schizophrenia and other psychotic disorders. It is administered via intramuscular injection and provides sustained release over several weeks, improving patient compliance in chronic psychiatric treatment. Due to its potent dopamine D2 receptor antagonism, it helps control positive symptoms of psychosis such as hallucinations, delusions, and thought disturbances. Its long half-life makes it suitable for depot therapy in stable patients requiring maintenance treatment. Not commonly used as a first-line agent due to potential extrapyramidal side effects and the availability of newer atypical antipsychotics.